Seaport Therapeutics (NASDAQ:SPTX) Director Buys $235,820.00 in Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Director Robert Hombach acquired 13,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the transaction, the director directly owned 13,000 shares in the company, valued at approximately $235,820. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seaport Therapeutics Stock Performance

NASDAQ SPTX opened at $18.97 on Wednesday. Seaport Therapeutics, Inc. has a 12-month low of $14.85 and a 12-month high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last released its quarterly earnings data on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($10.64) by $0.30.

Analysts Set New Price Targets

SPTX has been the subject of a number of analyst reports. Citigroup assumed coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price target for the company. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. JPMorgan Chase & Co. assumed coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, BNP Paribas Exane downgraded shares of Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Seaport Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $35.50.